You are here: Industry Insights > Samsung Biologics

News List

Samsung Biologics and ImmuneOncia Expand Partnership contractpharma
July 16, 2020
Sign multi-product development and manufacturing agreement for five candidate molecules.
GSK Partners with Samsung Biologics contractpharma
May 28, 2020
Inks $231 million deal to secure additional manufacturing capacity for biopharmaceutical portfolio.
GlaxoSmithKline signs manufacture deal with Samsung Biologics pharmaceutical-technology
May 26, 2020
GlaxoSmithKline has signed an agreement with South Korea-based Samsung Biologics for additional capacity to manufacture and supply its biopharmaceutical therapies.
Samsung Biologics Earnings to Beat Consensus Again, Continues to Sign New Projects with Enhanced Virtual Support prnasia
April 22, 2020
Samsung Biologics (KRX: 207940.KS) announced Q1 earnings results on Monday, April 20th. The company posted consolidated sales of 207.2 billion Korean Won, operating profit of 62.6 billion Korean Won, and net income of 39.1 billion Korean Won.
Vir selects Samsung Biologics to produce Covid-19 antibodies pharmaceutical-technology
April 14, 2020
Immunology company Vir Biotechnology has selected South Korea-based Samsung Biologics for large-scale production of antibodies to potentially treat Covid-19.
Samsung Biologics and Vir Biotechnology Enter into Agreement for Large Scale Manufacture of SARS-COV-2 Antibodies for Potential COVID-19 Treatment fiercepharma
April 13, 2020
Samsung Biologics (207940.KS) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services for Vir's SARS-CoV-2 monoclonal antibody (mAb) program.
Samsung Biologics, PharmAbcine Enter Antibody Pact contractpharma
April 07, 2020
To develop and manufacture PMC-402, a next-gen therapeutic antibody candidate to treat oncology and neovascular disorders.
Samsung Biologics Appoints BD VP for CDO Biz contractpharma
April 01, 2020
Ms. Yang brings 20 years of experience in marketing, sales, and business development at global pharmaceutical companies.
Samsung Biologics Adds Greater Expertise and Diversity to Its Board prnasia
March 20, 2020
Samsung Biologics (207940.KS) announced the appointment and expansion of its board of directors at its 9th annual general meeting of shareholders that took place on March 20th.
Samsung Biologics, APRINOIA Enter mAb Pact contractpharma
March 18, 2020
Samsung will provide cell line development, process development, cGMP manufacturing to IND filing support, for Alzheimer's antibody candidate.

Previous page 1 2 3 4 5 6 Next page